ETH Zurich & Paul Scherrer Institute Patent Landscape: A Comprehensive Intellectual Property & Deep-Tech Innovation Analysis
An in-depth analysis of 2,204 patent documents spanning five decades of pioneering Swiss research — from targeted radiopharmaceuticals and energy storage systems through medical imaging, photonics, heterogeneous catalysis, materials science, and nanofabrication — mapping the ETH Zurich ecosystem's global IP portfolio across 15 jurisdictions and 415 distinct patent families.
Executive Summary: ETH Zurich & Paul Scherrer Institute Patent Portfolio — Five Decades of Science-Driven IP at Europe's Frontier Research Ecosystem
ETH Zurich (Eidgenössische Technische Hochschule Zürich) and its affiliated Paul Scherrer Institute (PSI) — Switzerland's most important technical university and Europe's largest research centre for natural and engineering sciences — have together built an intellectual property portfolio that stands as one of the most scientifically distinguished and commercially impactful in the global academic IP landscape. This patent landscape report, prepared by IIPRD as an exemplary technology intelligence analysis, examines a corpus of 2,204 patent documents organised across 415 distinct patent families, representing over five decades of inventive output from this world-leading Swiss research ecosystem spanning priority filings from 1976 through 2024.
The portfolio's most defining characteristic is its extraordinary depth of scientific diversity — a hallmark of research institutions operating at the frontier of multiple scientific disciplines simultaneously. The IP estate spans six major technology domains: pharmaceutical chemistry and targeted therapeutics (A61K — 210 IPC documents; A61N — 77 documents), encompassing PSI's globally recognised radiopharmaceutical programme for targeted alpha and beta therapies; biochemistry and molecular biology (C12N — 139 documents) reflecting ETH Zurich's fundamental life sciences research; analytical and diagnostic instrumentation (G01N — 128 documents); electrochemical energy storage (H01M — 112 documents) anchored in PSI's battery and fuel cell research; medical imaging and radiation physics (A61B, G01T — 88 and 40 documents respectively); and materials science and catalysis (B01J — 64 documents; C08J — 53 documents).
The legal status profile — 377 granted (17.1%), 1,258 lapsed (57.1%), 304 expired (13.8%), 180 pending (8.2%), 85 revoked (3.9%) — reflects the characteristic IP lifecycle of a research institution: a high historical filing rate across fundamental and applied science, with natural portfolio rationalisation as commercial partners acquire licences on most valuable innovations while remaining IP lapses or reaches statutory term. The 557 alive patents (25.3%) represent the currently enforced and commercially active estate. Geographically, EPO (441), WIPO PCT (337), and the United States (332) anchor the filing strategy — the three-jurisdiction combination that maximises market coverage for research-intensive IP seeking commercial licensing partners across pharma, energy, and instrumentation sectors.
This patent landscape analysis provides critical intelligence for IP professionals, life science investors, energy technology strategists, academic licensing officers, and competitive intelligence analysts seeking to understand the scope, composition, and commercial trajectory of Switzerland's premier deep-tech intellectual property ecosystem.
Five Decades of Swiss Research Innovation: The ETH–PSI Filing Surge from Emerging Technology to Global IP Leadership
The temporal distribution of the ETH Zurich–Paul Scherrer Institute patent portfolio reveals a filing history that maps with remarkable precision onto the evolution of Swiss federal research investment priorities over five decades. The portfolio's earliest priority filings — beginning in 1976 and building steadily through the 1980s and early 1990s — establish the foundational IP in particle physics instrumentation, early photonics research, and fundamental chemical synthesis that would anchor PSI's and ETH's first generation of commercial licensing partnerships.
The modern IP acceleration begins decisively in 1997–2000, when annual priority filings rose from 68 to 91, coinciding with the Swiss National Science Foundation's (SNF) strategic investment in translational research infrastructure and the commercialisation of ETH's landmark achievements in combinatorial chemistry, enzymatic synthesis, and early fuel cell technology. The portfolio's peak priority filing year was 2005 with 176 filings — an extraordinary output for a research institution and a figure that reflects ETH Zurich's emergence as a global reference institution for robotics, photonics, materials science, and pharmaceutical technology simultaneously. The years 2003–2006 (98, 109, 176, 115 filings) represent the most intensive filing period in the portfolio's history, driven by PSI's radiopharmaceutical breakthrough programmes, ETH's photonics and integrated optics initiatives, and the collaborative battery research that would eventually underpin Switzerland's energy storage technology ecosystem.
The 2022–2024 moderation in priority filings (36, 16, 12) should not be interpreted as declining research output — rather, it reflects the standard 18–24 month lag between research completion and patent filing, meaning the 2021–2023 research output will appear in the 2023–2025 filing data. This interpretation is confirmed by the robust publication pipeline: 71 publications in 2025 and 27 already recorded in 2026, confirming that the prosecution pipeline remains actively producing new IP grants and published applications from recent priority filings in radiopharmacy, photonic computing, and solid-state battery architectures.
CPC Classification Reveals PSI's Radiopharmaceutical Dominance and ETH's Multi-Domain Deep-Tech Breadth
The Cooperative Patent Classification (CPC) distribution of the ETH–PSI patent portfolio delivers one of the most scientifically diverse technology maps in the academic IP landscape — a distribution that simultaneously reflects the applied research orientation of PSI and the fundamental science-to-technology pipeline of ETH Zurich. The dominant CPC class is A61K (193 documents — 14.4%) — pharmaceutical preparations — with an internal sub-distribution centred on A61K-051 (radiopharmaceutical preparations, 140+ documents), confirming PSI's global leadership in targeted radionuclide therapy. PSI's radiopharmaceutical programme — encompassing lutetium-177, actinium-225, and terbium-161 targeted therapy innovations — represents one of the most commercially consequential academic IP estates in European life science, with licensing revenues supporting ongoing research infrastructure investment and clinical translation partnerships with major pharmaceutical companies.
The H01M (140 documents) cluster — electrochemical cells and batteries — is the portfolio's second-largest CPC class and its most strategically timely. These documents capture PSI's and ETH's decade-long investment in solid-state electrolyte design, lithium-sulphur battery architecture, and proton exchange membrane fuel cell innovations — research domains that have become commercially critical as global energy transition investment has accelerated. The H01M patents encompass novel ceramic electrolyte compositions, electrode interface engineering innovations, and multi-layer cell architectures that are actively sought by battery manufacturers, automotive OEMs, and energy storage system integrators pursuing next-generation cell chemistry beyond lithium-ion.
The A61B (123 documents) — medical imaging and surgical instruments — and G01T (47 documents) — radiation and nuclear measurement — together represent PSI's comprehensive medical physics IP: X-ray free electron laser (SwissFEL) applications, proton therapy planning algorithms, synchrotron-based imaging innovations, and radiation dosimetry instrumentation that define the frontier of medical imaging technology. The G03F (50 documents) photolithography cluster reflects ETH Zurich's internationally recognised contributions to extreme ultraviolet (EUV) lithography, photomask technology, and nanofabrication process innovation — patent assets of acute commercial relevance to the semiconductor manufacturing industry's transition to sub-7nm process nodes.
IPC Analysis Confirms A61K Pharmaceutical Leadership While Revealing the Depth of ETH's Biochemistry and Bioengineering IP
The International Patent Classification (IPC) distribution provides the cross-jurisdictional view of the ETH–PSI technology taxonomy, applied by examiners across the EPO, USPTO, JPO, CNIPA, and WIPO in the portfolio's primary filing jurisdictions. The A61K dominance (210 documents) is even more pronounced in IPC than in CPC — reflecting the IPC system's broader categorisation of pharmaceutical preparations that captures not only PSI's radiopharmaceutical innovations but also ETH's drug delivery and formulation research that may be assigned to more specific CPC sub-classes. This A61K concentration confirms pharmaceutical technology as the single most commercially significant IP domain in the entire ETH ecosystem portfolio.
The C12N (139 documents) IPC cluster — nucleic acids, peptides, proteins, and microorganisms — provides the most important insight unique to IPC analysis in this portfolio. The substantial C12N presence reflects ETH Zurich's extensive molecular biology research spanning recombinant protein expression systems, gene editing technologies (including CRISPR-adjacent innovations), synthetic biology platforms, and enzyme engineering innovations developed across ETH's network of life science professorial chairs. These C12N patents represent some of the highest-value IP assets in the portfolio for biopharmaceutical licensing — covering foundational enabling technologies relevant to the production of antibody fragments, fusion proteins, and next-generation biologic therapeutics.
The co-appearance of G01N (128 documents) — chemical and physical analytical measurement — alongside H01M (112 documents) and A61B (88 documents) in the IPC top-six confirms the three-pillar structure of PSI's technology IP: analytical instrumentation for synchrotron-based research applications; electrochemical energy storage for sustainable energy systems; and medical physics/imaging for clinical translation. The C07K (79 documents) cluster — peptides and antibody structures — and B01J (64 documents) — heterogeneous catalysis — complete a profile that encompasses both the biomedical and physical science dimensions of ETH's interdisciplinary research mission.
EPO-First Filing Strategy: How ETH and PSI's Jurisdiction Architecture Reflects the Commercial Priorities of European Academic IP Licensing
The geographic distribution of the ETH–PSI patent portfolio presents one of the most instructive filing strategies in the academic IP landscape — a jurisdiction map that reflects both the commercial reality of research institution licensing and the specific market priorities of the technology sectors in which ETH and PSI most actively innovate. The European Patent Office leads with 441 documents (20.0%) — an EPO-first strategy that provides simultaneous protection across 38 member states through a single prosecution process, maximising jurisdictional breadth at minimum cost for institutions whose licensing partners are predominantly European pharmaceutical, energy, and industrial technology companies. The EPO's central role is particularly critical for PSI's radiopharmaceutical IP, where the primary commercial licensing candidates — major European pharma companies such as Novartis, Bayer, and AAA — operate from EPO member states and require EPO patents for their technology in-licensing programmes.
The WIPO PCT route (337 documents — 15.3%) reflects ETH's and PSI's standard approach to maximising international protection flexibility at lowest upfront cost — filing PCT applications to preserve national phase entry options across 150+ jurisdictions while awaiting commercial interest from potential licensees. The United States (332 documents — 15.1%) — nearly matching WIPO in document count — confirms the US as the indispensable single-country patent jurisdiction for technology commercialisation across all of ETH's and PSI's primary sectors: US pharmaceutical licensing, US semiconductor and lithography technology markets, and US energy storage investment are all critically dependent on USPTO-granted patent protection.
Japan (191 documents) and China (126 documents) reflect the global market reach of ETH's and PSI's most commercially advanced technology areas. Japan's substantial presence is driven primarily by photonics and battery technology filings — sectors where Japanese companies (Sony, Murata, Panasonic, Sumitomo Chemical) are major commercial licensing targets. China's growing representation reflects the increasing recognition of Chinese market protection value for energy storage and medical imaging technologies in which Chinese companies have become significant commercial actors. The Australia (103 documents) presence is notably high relative to Australia's market size and reflects PSI's radiopharmaceutical licensing activity with Australian nuclear medicine companies.
Research Institution IP Lifecycle: Understanding ETH–PSI's Lapsed Majority as Strategic Portfolio Pruning, Not Abandonment
The legal status distribution of the ETH–PSI portfolio requires careful contextualisation — the dominant LAPSED category (1,258 documents — 57.1%) is the most important and most frequently misinterpreted metric in academic patent landscape analysis. For research institutions, lapsing patents is not a sign of IP management failure; it is a deliberate and economically rational response to the distinctive lifecycle of research-generated IP. When a patent's commercial licensing prospect does not materialise within 3–5 years post-grant — because the target application has been superseded by newer technology, because the technology has transferred to a commercial partner who now manages continuation prosecution directly, or because the original research direction has evolved beyond the claims — research institutions rationally cease paying maintenance fees rather than sustaining the cost of a portfolio that has served its strategic purpose of establishing priority date protection and disclosure.
The 377 granted patents (17.1%) represent the commercially active enforcement-ready assets currently generating or positioned to generate licensing revenue. For an institution of ETH's and PSI's scale, a grant count of 377 across multiple high-value technology sectors represents a substantial and commercially significant IP arsenal, particularly given that the ETH ecosystem's most valuable granted patents in radiopharmaceuticals, solid-state batteries, and EUV lithography occupy technology domains where single patent licences can generate revenue in the tens to hundreds of millions of euros over their commercial lifetime.
The 180 pending patents (8.2%) — representing the current active prosecution pipeline in the most recent priority filing cohorts (2019–2024) — signals continued strong innovation output across PSI's targeted alpha therapy programmes, ETH's photonic computing research, and joint ETH-PSI solid-state energy storage initiatives. The 85 revoked patents (3.9%) confirm that ETH's and PSI's most commercially significant granted patents have attracted post-grant challenges from pharmaceutical, semiconductor, and energy sector competitors — an indirect measure of the commercial importance of the underlying innovations.
25.3% Alive Ratio: The Active Commercial Core of a Research Institution Portfolio Optimised for Technology Transfer
The 557 alive patents (25.3%) within the ETH–PSI portfolio represent the currently commercially relevant and legally enforceable IP estate — a concentrated, high-quality collection of granted patents and pending applications that encompasses the institution's most commercially advanced and scientifically current innovations. The 25.3% alive ratio is broadly consistent with the established patterns of university and public research institution patent portfolios globally, where the active maintenance of approximately one-quarter of the total cumulative filing history reflects the selectivity of ongoing commercialisation investment relative to the broader historical research output.
The 557 alive documents span the complete spectrum of the ETH ecosystem's current commercial technology transfer activity: PSI's targeted radionuclide therapy patent portfolio, which is actively licensed to pharmaceutical companies pursuing Lutetium-177 and Actinium-225 theranostic programmes; ETH's photonic integrated circuit and EUV lithography innovations positioned for semiconductor industry licensing; the ETH–PSI solid-state battery and proton exchange membrane fuel cell patents pursued by energy storage companies and automotive OEMs; and ETH's synthetic biology and biocatalysis innovations licensed to industrial biotechnology and specialty chemical manufacturers.
The 1,647 dead patents (74.7%) encompass the natural lifecycle completions of the portfolio's earliest filings from the 1976–2000 era, as well as the strategically lapsed documents representing technology approaches superseded by subsequent generations of innovation. Critically, these dead patents — particularly the pre-2000 foundational filings — constitute an extensive published prior art landscape that creates significant defensive value: any competitor seeking to re-patent adjacent chemistry, device structure, or process innovations first disclosed in ETH's and PSI's historical patent publications faces the barrier of that rich prior art body, limiting the scope of newly issued competitor patents in ETH's core technology domains.
Patent Family Architecture: Singleton Research Filings and Multi-Jurisdictional Commercial Champions in the ETH Innovation Pipeline
Patent family analysis provides the most direct quantitative insight into ETH's and PSI's commercial prioritisation decisions — the number of jurisdictions in which an invention is prosecuted being the clearest indicator of the commercial confidence that technology transfer offices have assigned to each underlying innovation. The ETH–PSI family size distribution reveals a portfolio with a substantial singleton base (84 single-member families — 20.2% of all 415 families) primarily representing older filings from the portfolio's pre-2000 era, where international prosecution was less systematically pursued, and recent experimental filings where the commercial landscape has not yet been assessed.
The medium-family cohort — sizes 3–6, accounting for 131 families (31.6%) — represents the commercially important standard multi-jurisdictional protection tier: innovations that ETH's and PSI's technology transfer offices (ETH Transfer and PSI Technology Transfer) have determined warrant EPO + US + PCT minimum coverage based on demonstrated commercial interest from industrial partners. These 3–6 member families typically correspond to innovations that have already attracted licensing discussions with pharmaceutical, energy, or instrumentation companies, where the commercial upside justifies the investment in coordinated multi-jurisdictional prosecution.
At the high end of the distribution, families of size 15–37 members — a cohort of 11 families — represent the portfolio's most commercially critical innovations, each prosecuted across the maximum available jurisdiction set. The single maximum family of size 37 members represents the single most commercially important invention in the entire ETH–PSI portfolio — almost certainly corresponding to a core radiopharmaceutical composition or targeted therapy platform in PSI's clinical-stage development pipeline, where the global pharmaceutical market opportunity justifies prosecution across all major jurisdictions simultaneously. These large families represent the crown jewels of Switzerland's most important public research institution — the innovations most likely to generate transformative commercial licensing revenue across multiple decades of patent protection.
Institutional IP Ecosystem: How the PSI–ETH–Partners Architecture Mirrors Switzerland's Science-to-Market Translation Strategy
The assignee distribution within the ETH–PSI patent portfolio maps the multi-institutional architecture of Switzerland's premier science-to-market translation ecosystem — a network in which the Paul Scherrer Institute and ETH Zurich serve as the primary innovation generators while commercial partners, spin-offs, and affiliated institutions co-hold IP reflecting joint development investments. Paul Scherrer Institute (all variants combined — 1,130 documents, 51.3%) is by a wide margin the portfolio's dominant filing entity, reflecting PSI's status as Europe's largest multidisciplinary research centre with a particularly prolific IP output in radiopharmaceuticals, synchrotron instrumentation, neutron science, and electrochemical energy systems. PSI's IP filing volume — remarkable for a research centre without teaching or student tuition revenue — is sustained by its unique position as operator of the Swiss Light Source (SLS), the Swiss Spallation Neutron Source (SINQ), the SwissFEL free-electron laser, and the cyclotron-based radiopharmaceutical production facility that generates both commercial radioisotope sales and pharmaceutical licensing revenue.
ETH Zurich (all variants combined — approximately 690 documents, 31.3%) encompasses the full breadth of ETH's professorial research: photonics and optical communications (ETH Zurich photonics group), mechanical engineering and robotics (Sensory-Motor Systems Lab, Robotic Systems Lab), computational biology and systems biology (ETH D-BSSE), environmental science (Institute of Biogeochemistry), food science (Laboratory of Food Biotechnology), and materials science (Complex Materials group). The breadth of ETH's assignee contribution — spanning a wider range of CPC classes than PSI — reflects the multi-disciplinary nature of ETH's 16 departments and the decentralised IP management approach through ETH Transfer, which supports faculty-level patent prosecution across all engineering and natural science domains.
Michelin (combined — 79 documents) is the portfolio's most commercially significant industrial co-assignee, reflecting a multi-year collaborative research agreement between PSI and Michelin on sustainable tire compound chemistry, renewable carbon black synthesis, and bio-based polymer innovations — a partnership that has generated substantial jointly owned IP at the boundary of materials science (C07F, C08J) and sustainable chemistry. The presence of Mallinckrodt (36 documents) — a nuclear medicine imaging and radiopharmaceutical company — confirms the depth of PSI's historical commercial partnerships in targeted radionuclide therapy. ITM Munich (23 documents) and EPFL (31 documents) represent respectively PSI's radiopharmaceutical commercialisation partner for Tb-161 and Lu-177 targeted therapies, and the broader Swiss academic innovation ecosystem's complementary IP contributions.
A pending European patent application by Paul Scherrer Institute and Amphilix — covering advanced targeted radiopharmaceutical compositions for cancer theranostics. This filing builds on PSI's internationally recognized expertise in Actinium-225 and novel radionuclide chelator chemistry, protecting innovations in radiometal complexation and tumour-targeting vector design relevant to the rapidly growing targeted alpha therapy market, which is expected to exceed $5 billion in annual revenue by 2030 as clinical programmes progress through registration trials.
A recently granted European patent by ITM Munich and Paul Scherrer Institute covering Terbium-161 radiopharmaceutical compositions for targeted beta-minus therapy — PSI's landmark contribution to the emerging Tb-161 theranostic platform that enables simultaneous imaging and treatment using the same molecule. Terbium-161's unique combination of low-energy beta particles and Auger electrons makes it particularly effective for targeting small tumour clusters and micrometastases, representing a next-generation advantage over Lutetium-177 in specific oncology indications.
A recently granted Korean patent by ETH Zurich and Paul Scherrer Institute jointly — covering advanced photonic integrated circuit and nonlinear optical waveguide innovations. This patent protects ETH and PSI's contributions to the rapidly advancing field of photonic computing and optical signal processing, where integrated nonlinear optical components enable ultra-fast signal modulation speeds critical for next-generation optical communications networks and photonic computing accelerators for AI workloads.
A recently granted US patent by Paul Scherrer Institute covering novel therapeutic compound compositions for treatment of infectious disease — protecting small molecule innovations with demonstrated activity against drug-resistant parasitic organisms. This patent reflects PSI's productive interdisciplinary research at the intersection of synthetic chemistry, structural biology using synchrotron X-ray crystallography (Swiss Light Source), and pharmacology — exemplifying how PSI's unique research infrastructure enables drug discovery programmes that generate both fundamental insights and commercially protectable pharmaceutical IP.
Innovation Trajectory: ETH Zurich & PSI's IP Evolution from Particle Physics Roots to Global Deep-Tech Commercialisation
The innovation trajectory of ETH Zurich and the Paul Scherrer Institute, as illuminated through this comprehensive patent landscape analysis spanning 2,204 documents and five decades, is a masterclass in how world-class research institutions can translate fundamental scientific discovery into commercially significant intellectual property across multiple technology generations. From the earliest proton therapy and optical fibre patents of the 1970s and 1980s through to the cutting-edge targeted alpha therapy radiopharmaceuticals, photonic computing platforms, and solid-state energy storage innovations of the 2020s, the ETH–PSI portfolio traces a continuous arc of scientific leadership converted into IP assets of global commercial consequence.
The portfolio's current strategic focus — concentrated in the convergence of radiopharmaceutical science, photonic integration, and electrochemical energy systems — positions ETH and PSI at the intersection of the three deepest technology investment waves of the coming decade: the oncology biotech revolution, the photonic computing surge driven by AI workload growth, and the energy storage transition underpinning global decarbonisation. With 180 pending applications representing the most recent research cohorts, and a record 71 publications in 2025 confirming the prosecution pipeline's maturity, the ETH–PSI IP estate is positioned for its most commercially consequential grant harvest in the institution's history.
For IP professionals, life science investors, energy technology strategists, semiconductor industry licensees, and competitive intelligence analysts, the ETH Zurich and Paul Scherrer Institute patent landscape represents one of Europe's most scientifically distinguished and commercially undervalued intellectual property collections — an IP estate whose full commercial potential is increasingly recognised as the theranostics market expands, photonic computing scales, and solid-state battery technology transitions from laboratory innovation to industrial production at global scale.